Stock 002252 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Shanghai RAAS Blood Products Co., Ltd. Stock

Equities

002252

CNE100000C31

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 2024-12-11 		5-day change 1st Jan Change
7.650 CNY +2.14% Intraday chart for Shanghai RAAS Blood Products Co., Ltd. +1.59% -4.38%
Dec. 05 Shanghai RAAS Blood Products Unit's Fibrinogen Drug Under NMPA's Clinical Inspection MT
Nov. 28 RAAS Blood Products Gets China Approval for Clinical Trial of Human Fibrinogen MT

Valuation: Shanghai RAAS Blood Products Co., Ltd.

Capitalization 50.53B 6.96B 6.64B 6.15B 5.46B 9.84B 590B 10.93B 76.45B 28.31B 243B 26.14B 25.56B 1,061B P/E ratio 2024 *
20.7x
P/E ratio 2025 * 19.1x
Enterprise value 44.64B 6.15B 5.86B 5.44B 4.82B 8.69B 521B 9.66B 67.54B 25.01B 214B 23.1B 22.59B 938B EV / Sales 2024 *
5.2x
EV / Sales 2025 * 4.4x
Free-Float
69.51%
Yield 2024 *
0.2%
Yield 2025 * 0.2%
More valuation ratios * Estimated data

Chart: Shanghai RAAS Blood Products Co., Ltd.

Dynamic Chart

Latest news: Shanghai RAAS Blood Products Co., Ltd.

Shanghai RAAS Blood Products Unit's Fibrinogen Drug Under NMPA's Clinical Inspection Dec. 05 MT
RAAS Blood Products Gets China Approval for Clinical Trial of Human Fibrinogen Nov. 28 MT
Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 Oct. 28 CI
Shanghai RAAS Blood Products Sees Steady H1 Profit; Shares Down 3% Aug. 27 MT
Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 Aug. 27 CI
Shanghai RAAS Blood Products Co., Ltd. Announces Board Elections Jul. 30 CI
Grifols revises past financial records with equity value drop of $494 mln Jul. 30 RE
Haier Gets Regulatory Nod to Buy Controlling Stake in RAAS Blood Products Jun. 20 MT
RAAS Blood Products Renews Cooperation Deal With Spain's Grifols Jun. 18 MT
Haiyingkang Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. from Grifols, S.A.. Jun. 17 CI
GRIFOLS CEO SAYS CAN CONFIRM SHANGHAI RAAS TRANSACTION WILL CLO… May. 14 RE
Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 Apr. 29 CI
RAAS Blood Products' 2023 Profit Falls 5% Despite 21% Revenue Growth Apr. 29 MT
More news

Press Releases: Shanghai RAAS Blood Products Co., Ltd.

Shanghai RAAS Blood Products : Grifols and Shanghai RAAS close their strategic alliance in China 20-03-30 AQ
More press releases

News in other languages: Shanghai RAAS Blood Products Co., Ltd.

Grifols revisa sus cuentas financieras anteriores con una caída de valor de 494 millones de dólares Jul. 30
Point marchés-L'Europe clôture en hausse, l'économie de la zone euro montre des signes d'amélioration May. 06
Grifols dice se ha cumplido la debida diligencia en la venta de la participación en Shanghai RAAS  Mar. 01
Actualización de las fuertes variaciones del día: Drax y UMG seducen, mientras que Amadeus y Grifols decepcionan Feb. 29
Grifols dice que está en vías de reducir su ratio de deuda Feb. 29
More news

Quotes and Performance

1 day+2.14%
1 week+1.59%
Current month+1.73%
1 month-0.78%
3 months+12.17%
6 months+2.96%
Current year-4.38%
More quotes

Course Extremes

1 week
7.41
Extreme 7.41
7.70
1 month
7.35
Extreme 7.35
7.89
Current year
5.93
Extreme 5.93
8.68
1 year
5.93
Extreme 5.93
8.68
3 years
4.98
Extreme 4.98
8.68
5 years
4.98
Extreme 4.98
11.16
10 years
4.98
Extreme 4.98
26.67
More quotes

Managers and Directors: Shanghai RAAS Blood Products Co., Ltd.

Director TitleAgeSince
Jun Xu CEO
 Chief Executive Officer 60 -
Le Qi Chen DFI
 Director of Finance/CFO 37 2021-10-25
Hong Qiu IRC
 Investor Relations Contact - -
Manager TitleAgeSince
Yue Wen Zheng BRD
 Director/Board Member 62 2007-04-26
Tommy Trong Hoang BRD
 Director/Board Member 57 2020-05-20
Binh Hoang BRD
 Director/Board Member 50 2007-04-26
More insiders

ETFs: Shanghai RAAS Blood Products Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD ETF KraneShares Emerging Market Healthcare Index ETF - Distributing - USD
0.71% 2 M€ -14.14%
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD ETF KraneShares MSCI All China Health Care Index UCITS ETF - USD
0.69% 1 M€ -20.08% -
More ETFs: Shanghai RAAS Blood Products Co., Ltd.

Biopharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. Stock Shanghai RAAS Blood Products Co., Ltd.
+2.14%+1.59%-9.04%+18.24%6.82B
CSL LIMITED Stock CSL Limited
-0.85%-1.76%+4.75%-6.27%87B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-1.04%-1.86%+33.85%+5.33%47.69B
UCB Stock UCB
-0.25%-4.31%+134.92%+81.62%35.96B
BIOGEN INC. Stock Biogen Inc.
+0.29%-2.67%-36.36%-33.21%22.78B
INCYTE CORPORATION Stock Incyte Corporation
+0.12%-2.98%+26.93%+6.77%13.96B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-0.82%+0.96%+57.88%-37.62%13.37B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-0.86%-1.14%-29.68%-21.53%12.66B
ALTEOGEN INC. Stock ALTEOGEN Inc.
-3.14%-5.23%+316.78%+324.34%11.84B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
+0.30%+1.76%-51.78%-64.63%9.87B
Average -0.41%-0.10%+44.83%+27.30% 26.2B
Weighted average by Cap. -0.63%-1.11%+38.19%+17.30%
See all sector performances

Financials

2024 *2025 *
Net sales 8.58B 1.18B 1.13B 1.05B 927M 1.67B 100B 1.86B 12.98B 4.81B 41.21B 4.44B 4.34B 180B 9.41B 1.3B 1.24B 1.15B 1.02B 1.83B 110B 2.04B 14.24B 5.27B 45.2B 4.87B 4.76B 198B
Net income 2.43B 335M 320M 297M 263M 474M 28.44B 527M 3.68B 1.36B 11.69B 1.26B 1.23B 51.14B 2.68B 369M 352M 326M 289M 521M 31.25B 579M 4.05B 1.5B 12.85B 1.38B 1.35B 56.2B
Net Debt -5.88B -810M -773M -717M -636M -1.15B -68.71B -1.27B -8.9B -3.3B -28.26B -3.04B -2.98B -124B -9.07B -1.25B -1.19B -1.11B -980M -1.77B -106B -1.96B -13.73B -5.08B -43.58B -4.7B -4.59B -191B
More financial data * Estimated data

Company Profile

Logo Shanghai RAAS Blood Products Co., Ltd.
Shanghai RAAS Blood Products Co., Ltd. specializes in the research, development and manufacturing of plasma-derived therapeutics. The group's products include human albumin, immunoglobulin and coagulation factors (thrombin, fibrinogen, prothrombin and fibrin). China accounts for 96.6% of net sales.
Employees
3,254
Sector
Pharmaceuticals
Calendar
2025-04-24 - Q4 2024 Earnings Release (Projected)
More about the company

Quotes

Date Price Change Volume
24-12-10 7.650 ¥ +2.14% 63,061,580
24-12-10 7.490 ¥ +0.13% 46,203,810
24-12-09 7.480 ¥ -0.40% 40,735,450
24-12-06 7.510 ¥ +0.94% 32,525,530
24-12-05 7.440 ¥ -0.27% 24,106,900

End-of-day quote Shenzhen S.E., December 10, 2024

More quotes

Income Statement and Estimates

income-statement-evolution-chart SHANGHAI-RAAS-BLOOD-PRODU More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
C-
surperformance-ratings-light-chart SHANGHAI-RAAS-BLOOD-PRODUMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
7.650CNY
Average target price
6.400CNY
Spread / Average Target
-16.34%
Consensus
Profit revisions
estimates-change-chart SHANGHAI-RAAS-BLOOD-PRODU Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart SHANGHAI-RAAS-BLOOD-PRODU Company calendar
  1. Stock Market
  2. Equities
  3. 002252 Stock